AstraZeneca has provided more details on the COVID vaccine pause.
As StatNews reports, the participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.
Soriot went on to say that while the woman’s diagnosis has not been confirmed yet, she is improving and will likely be discharged from the hospital as early as Wednesday.
After ramping ovenight to erase the losses, AZN shares are sliding back on these new revelations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.